信迪利单抗联合安罗替尼对Ⅲb~Ⅳ期非小细胞肺癌患者的疗效及安全性分析  

Efficacy and Safety Analysis of Cindilimab Combined with Arotinib in Patients with StageⅢb toⅣNon-Small Cell Lung Cancer

作　　者：李敏[1] 邢玲[1] 郭丽芳[1] LI Min;XING Ling;GUO Lifang(The Second Affiliated Hospital of Zhengzhou University,Zhengzhou,450014)

机构地区：[1]郑州大学第二附属医院,450014

出　　处：《实用癌症杂志》2023年第5期850-854,共5页The Practical Journal of Cancer

摘　　要：目的探讨信迪利单抗联合安罗替尼在Ⅲb~Ⅳ期非小细胞肺癌(NSCLC)患者中的应用效果。方法选取Ⅲb~Ⅳ期NSCLC患者132例,根据治疗方案不同分为2组,其中对照组61例、研究组71例。对照组采用安罗替尼+紫杉醇方案化疗,研究组采用信迪利单抗+安罗替尼方案化疗,统计比较2组客观缓解率(ORR)、疾病控制率(DCR)、治疗前后肿瘤标志物[癌胚抗原(CEA)、癌抗原125(CA125)]水平、黏附分子[可溶性细胞间黏附分子-1(sICAM-1)、可溶性血管黏附分子-1(sVCAM-1)]含量、免疫指标(CD4^(+)、CD4^(+)/CD8^(+))、生存质量(FACT-L)及不良反应发生率。结果研究组ORR为66.20%、DCR为85.92%,高于对照组的49.18%、65.57%(P<0.05);治疗3个周期后研究组血清CEA、CA125水平及sICAM-1、sVCAM-1含量较对照组低(P<0.05);治疗3个周期后研究组CD4^(+)、CD4^(+)/CD8^(+)及FACT-L评分较对照组高(P<0.05);研究组不良反应发生率(23.94%)与对照组(26.23%)比较无显著差异(P>0.05)。结论信迪利单抗联合安罗替尼治疗Ⅲb~Ⅳ期NSCLC患者疗效显著,可降低肿瘤标志物表达水平,改善机体免疫功能,降低肿瘤转移风险,提高患者生存质量,且安全性良好。Objective To investigate the application effect of sintilimab combined with anlotinib in patients with stageⅢb~Ⅳnon-small cell lung cancer(NSCLC).Methods A total of 132 patients with stageⅢb toⅣNSCLC were selected and divided into 2 groups according to different treatment plans,including 61 patients in the control group and 71 patients in the study group.The control group was treated with the chemotherapy regimen of arotinib+paclitaxel,while the study group was treated with the chemotherapy regimen of cindilimab+arotinib,and the objective response rate(ORR),disease control rate(DCR),and tumor markers[carcinoembryonic]before and after treatment were compared between the 2 groups.Antigen(CEA),cancer antigen 125(CA125)]levels,adhesion molecules[soluble intercellular adhesion molecule-1(sICAM-1),soluble vascular adhesion molecule-1(sVCAM-1)]content,immune indicators(CD4^(+),CD4^(+)/CD8^(+)),quality of life(FACT-L)and incidence of adverse reactions.Results The ORR of the study group was 66.20%and the DCR was 85.92%,which were higher than those of the control group of 49.18%and 65.57%(P<0.05);After 3 cycles of treatment,the serum levels of CEA,CA125,sICAM-1 and sVCAM-1 in the study group were lower than those in the control group(P<0.05);After 3 cycles of treatment,the CD4^(+),CD4^(+)/CD8^(+)and FACT-L scores in the study group were higher than those in the control group(P<0.05);There was no significant difference in the incidence of adverse reactions between the study group(23.94%)and the control group(26.23%)(P>0.05).Conclusion Sintilimab combined with anlotinib has significant curative effect in the treatment of stageⅢb~ⅣNSCLC patients,which can reduce the expression level of tumor markers,improve the body's immune function,reduce the risk of tumor metastasis,and improve the quality of life of patients with good safety.

关 键 词：非小细胞肺癌 信迪利单抗 安罗替尼 客观缓解率 肿瘤标志物 免疫指标 

分 类 号：R734.2[医药卫生—肿瘤]